US4359460A
Expired / Lapsed
US
⏱️ 0.0 years remaining
6'-(1-Adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose sulfate salts
Assignee: Wyeth Holdings LLC
•
Filing: 1981-10-13
•
Granted: 1982-11-16
•
Expires: 2001-10-13
Abstract
Abstract 6'-(1-Adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose sulfate salts, useful as complement inhibitors, and the process for making such compounds.
Inventors
- 👤 Vijay G. Nair
- 👤 Seymour Bernstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 11:30
CPC Classifications
C; C07; C07H; C07H3/00; C07H3/04
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
65 words
A compound selected from those of the formula: ##STR5## wherein A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 2
Dependent Claim
65 words
A compound selected from those of the formula: ##STR5## wherein A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 3
Dependent Claim
12 words
The compound according to claim 1, 6'-(1-adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose, heptakis (H-sulfate), heptasalt with trimethylamine.
Claim 4
Dependent Claim
11 words
The compound according to claim 1, 6'-(1-adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose, heptakis (H-sulfate), heptasodium salt.
Claim 5
Independent Claim
92 words
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a compound selected from those of the formula: ##STR6## wherein A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 6
Independent Claim
92 words
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a compound selected from those of the formula: ##STR6## wherein A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 7
Independent Claim
89 words
A method of inhibiting the complement system in a warm-blooded animal which comprises administering to said warm-blooded animal an effective complement inhibiting amount of a compound selected from those of the formula: ##STR7## wherein A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 8
Independent Claim
89 words
A method of inhibiting the complement system in a warm-blooded animal which comprises administering to said warm-blooded animal an effective complement inhibiting amount of a compound selected from those of the formula: ##STR7## wherein A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 9
Dependent Claim
18 words
The method according to claim 4 or 5, wherein the compound is 6'-(1-adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose, heptakis (H-sulfate), heptasalt with trimethylamine.
Claim 10
Dependent Claim
17 words
The method according to claim 4 or 5, wherein the compound is 6'-(1-adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose, heptakis (H-sulfate), heptasodium salt.
Claim 11
Dependent Claim
12 words
The method according to claim 5, wherein the compound is administered internally.
Claim 12
Dependent Claim
12 words
The method according to claim 5, wherein the compound is administered topically.
Claim 13
Dependent Claim
16 words
The method according to claim 5, wherein the compound is administered periodontally in the oral cavity.
Claim 14
Dependent Claim
12 words
The method according to claim 5, wherein the compound is administered intra-articularly.
Claim 15
Dependent Claim
12 words
The method according to claim 5, wherein the compound is administered parenterally.
Claim 16
Dependent Claim
226 words
A process for the preparation of a compound of the formula: ##STR8## wherein A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ), which comprises suspending 6-O-α-D-galactopyranosyl-α-D-glucopyranose in pyridine, adding calcium sulfate, heating at 75°-100° C. for 15-60 minutes, adding trityl chloride, heating and stirring for 2 hours, cooling, adding acetic anhydride, standing overnight, collecting solid 6-O-(6-O-trityl-α-D-galactopyranosyl)-α-D-glucopyranose, heptaacetate, heating with glacial acetic acid at 40°-70° C. for 4 hours, cooling and extracting with dichloromethane, evaporating extracts to a glass and purifying giving 6-O-α-D-galactopyranosyl-α-D-glucopyranose, heptaacetate, treating with 1-adamantoylchloride in pyridine with stirring for 20 hours, pouring into ice, giving 6'-(1-adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose, heptaacetate, dissolving in methanol:water:triethylamine (6:2:3), stirring for 24 hours and evaporating, giving 6'-(1-adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose, adding to a mixture of trimethylamine-sulfur trioxide in dimethylformamide and stirring for 24 hours, giving 6'-(1-adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose, heptakis (H-sulfate), heptasalt with trimethylamine and treating with an alkali metal or alkaline earth metal cation-containing compound or ammonia or a substituted ammonia other than trimethylamine selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 17
Dependent Claim
226 words
A process for the preparation of a compound of the formula: ##STR8## wherein A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ), which comprises suspending 6-O-α-D-galactopyranosyl-α-D-glucopyranose in pyridine, adding calcium sulfate, heating at 75°-100° C. for 15-60 minutes, adding trityl chloride, heating and stirring for 2 hours, cooling, adding acetic anhydride, standing overnight, collecting solid 6-O-(6-O-trityl-α-D-galactopyranosyl)-α-D-glucopyranose, heptaacetate, heating with glacial acetic acid at 40°-70° C. for 4 hours, cooling and extracting with dichloromethane, evaporating extracts to a glass and purifying giving 6-O-α-D-galactopyranosyl-α-D-glucopyranose, heptaacetate, treating with 1-adamantoylchloride in pyridine with stirring for 20 hours, pouring into ice, giving 6'-(1-adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose, heptaacetate, dissolving in methanol:water:triethylamine (6:2:3), stirring for 24 hours and evaporating, giving 6'-(1-adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose, adding to a mixture of trimethylamine-sulfur trioxide in dimethylformamide and stirring for 24 hours, giving 6'-(1-adamantanecarboxylate)-6-O-α-D-galactopyranosyl-α-D-glucopyranose, heptakis (H-sulfate), heptasalt with trimethylamine and treating with an alkali metal or alkaline earth metal cation-containing compound or ammonia or a substituted ammonia other than trimethylamine selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-11-15 | 1986-05-17 | 1986-11-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-11-15 | 1990-05-17 | 1990-11-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-11-15 | 1994-05-17 | 1994-11-16 | $7700.00 | Window Closed / Lapsed |